GALT

Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.

Wall Street analysts forecast GALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GALT is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Galectin Therapeutics Inc revenue for the last quarter amounts to -4.20M USD, decreased -53.70 % YoY.

Galectin Therapeutics Inc. EPS for the last quarter amounts to USD, decreased % YoY.

Galectin Therapeutics Inc (GALT) has 15 emplpoyees as of January 10 2026.

Today GALT has the market capitalization of 203.09M USD.